A personalised computational model of the impact of COVID-19 on lung function under mechanical ventilation.

A personalised computational model of the impact of COVID-19 on lung function under mechanical ventilation.

Publication date: Oct 15, 2024

This work proposes a modelling framework to analyse flow and pressure distributions throughout the lung of mechanically ventilated COVID-19 patients. The methodology involves: segmentation of the lungs and major airways from patient CT images; a volume filling algorithm that creates a dichotomous airway network in the remaining volume of the lung; an estimate of resistance and compliance within the lung based on Hounsfield unit values from the CT scan; and a computational fluid dynamics model to analyse flow, lung inflation, and pressure throughout the airway network. Mechanically ventilated patients with differing progression and severity of the disease were simulated. The results indicate that the flow distribution within the lung can be significantly affected when there are competing types of lung damage. These competing types are primarily fibrosis-like lung damage that creates higher resistance and lower compliance in that region; and emphysema, which causes a decrease in resistance and increase in compliance. In a patient with severe disease, the model predicted an increase in inflation by 33% in an area affected by emphysema-like conditions. This could increase the risk of alveolar rupture. The framework could readily be adapted to study other respiratory diseases. Early interventions in critical respiratory care could be facilitated through such efficient patient-specific modelling approaches.

Open Access PDF

Concepts Keywords
Airways Computational fluid dynamics
Clinical COVID-19
Competing Lung modelling
Fibrosis Mechanical ventilation
Inflation Reduced-order modelling

Semantics

Type Source Name
disease MESH COVID-19
disease IDO algorithm
disease MESH fibrosis
disease MESH emphysema
disease MESH causes
disease MESH respiratory diseases
drug DRUGBANK Coenzyme M
disease MESH morbidities
disease MESH cardiovascular diseases
disease MESH chronic kidney disease
disease MESH cancer
disease MESH obesity
disease MESH long COVID
disease MESH complications
disease MESH pneumonia
disease MESH pleural effusion
disease IDO blood
drug DRUGBANK Oxygen
drug DRUGBANK Carbon dioxide
disease MESH acute respiratory distress syndrome
disease MESH respiratory failure
disease IDO intervention
disease IDO process
disease MESH interstitial pneumonia
disease MESH uncertainty
disease MESH coma
disease MESH COPD
disease MESH Hypothyroidism
disease MESH Arthritis
disease MESH Chronic Fatigue Syndrome
drug DRUGBANK Methionine
drug DRUGBANK Medical air
disease MESH total lung capacity
disease MESH anomalies
disease MESH overweight
disease MESH idiopathic pulmonary fibrosis
disease MESH ramp
disease MESH auto peep
disease MESH pulmonary fibrosis
disease MESH lung disease
disease MESH autoimmunity
disease IDO role
disease MESH lung injury
disease MESH idiopathic interstitial pneumonias

Original Article

(Visited 4 times, 1 visits today)